Lecap Asset Management Ltd. Acquires Shares of 36,155 Royalty Pharma plc (NASDAQ:RPRX)

Lecap Asset Management Ltd. bought a new stake in Royalty Pharma plc (NASDAQ:RPRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 36,155 shares of the biopharmaceutical company’s stock, valued at approximately $1,023,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Xponance Inc. boosted its holdings in Royalty Pharma by 1.9% in the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock valued at $836,000 after acquiring an additional 606 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 655 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Royalty Pharma by 10.8% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 887 shares during the period. Meeder Advisory Services Inc. raised its stake in shares of Royalty Pharma by 12.7% during the second quarter. Meeder Advisory Services Inc. now owns 8,223 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 926 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Royalty Pharma by 362.7% in the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 943 shares during the period. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

RPRX has been the subject of a number of analyst reports. Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. The Goldman Sachs Group lifted their price objective on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Royalty Pharma has an average rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX opened at $27.36 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The stock has a market capitalization of $16.24 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 4.12 and a beta of 0.46. The stock has a 50 day moving average price of $28.02 and a 200 day moving average price of $27.65. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The firm had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. During the same quarter in the previous year, the firm earned $0.85 earnings per share. Analysts predict that Royalty Pharma plc will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma’s payout ratio is presently 74.34%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.